MwanzoABBV34 • BVMF
add
Abbvie Inc BDR
Bei iliyotangulia
R$ 62.90
Bei za siku
R$ 62.90 - R$ 63.90
Bei za mwaka
R$ 54.36 - R$ 79.10
Thamani ya kampuni katika soko
322.03B USD
Wastani wa hisa zilizouzwa
elfu 5.63
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 13.34B | 8.39% |
Matumizi ya uendeshaji wa biashara | 5.28B | 8.44% |
Mapato halisi | 1.29B | -6.06% |
Kiwango cha faida halisi | 9.64 | -13.31% |
Mapato kwa kila hisa | 2.46 | 6.49% |
EBITDA | 6.10B | 11.89% |
Asilimia ya kodi ya mapato | 22.40% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 5.18B | -71.35% |
Jumla ya mali | 136.16B | -8.54% |
Jumla ya dhima | 134.70B | -4.35% |
Jumla ya hisa | 1.46B | — |
hisa zilizosalia | 1.77B | — |
Uwiano wa bei na thamani | 78.62 | — |
Faida inayotokana na mali | 7.48% | — |
Faida inayotokana mtaji | 14.21% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 1.29B | -6.06% |
Pesa kutokana na shughuli | 1.64B | -59.53% |
Pesa kutokana na uwekezaji | -735.00M | 92.33% |
Pesa kutokana na ufadhili | -1.26B | -111.63% |
Mabadiliko halisi ya pesa taslimu | -349.00M | -106.64% |
Mtiririko huru wa pesa | 1.12B | -73.12% |
Kuhusu
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira, approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis and administered via injection; Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases; Rinvoq, used to treat arthritis; and Botox. Its other major products include Imbruvica to treat cancer, Vraylar to treat schizophrenia and bipolar disorder, Venclexta to treat leukemia and lymphoma, Mavyret to treat Hepatitis C, and Epkinly, a blood-cancer therapy developed in partnership with Genmab. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev and tavapadon.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. Wikipedia
Ilianzishwa
10 Apr 2012
Makao Makuu
Tovuti
Wafanyakazi
55,000
